Search Results - "Berclaz, Pierre‐Yves"

A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti–Interleukin‐17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors by Genovese, Mark C., Greenwald, Maria, Cho, Chul‐Soo, Berman, Alberto, Jin, Ling, Cameron, Gregory S., Benichou, Olivier, Xie, Li, Braun, Daniel, Berclaz, Pierre‐Yves, Banerjee, Subhashis

“…Objective To evaluate ixekizumab, an anti–interleukin‐17A (anti–IL‐17A) monoclonal antibody, in 2 populations of rheumatoid arthritis (RA) patients:…”
Get full text

GM-CSF Autoantibodies and Neutrophil Dysfunction in Pulmonary Alveolar Proteinosis by Uchida, Kanji, Beck, David C, Yamamoto, Takashi, Berclaz, Pierre-Yves, Abe, Shuichi, Staudt, Margaret K, Carey, Brenna C, Filippi, Marie-Dominique, Wert, Susan E, Denson, Lee A, Puchalski, Jonathan T, Hauck, Diane M, Trapnell, Bruce C

“…Infection, especially with opportunistic microbes, is a prominent feature of pulmonary alveolar proteinosis; extrapulmonary infection suggests a systemic…”
Get full text

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate by Keystone, Edward C, Taylor, Peter C, Drescher, Edit, Schlichting, Douglas E, Beattie, Scott D, Berclaz, Pierre-Yves, Lee, Chin H, Fidelus-Gort, Rosanne K, Luchi, Monica E, Rooney, Terence P, Macias, William L, Genovese, Mark C

“…To investigate baricitinib (LY3009104, formerly INCB028050), a novel, oral inhibitor of JAK1/JAK2 in patients with moderate to severe rheumatoid arthritis (RA)…”
Get more information

AIR Inhaled Insulin Versus Subcutaneous Insulin by Wolzt, Michael, de la Peña, Amparo, Berclaz, Pierre-Yves, Tibaldi, Fabián S., Gates, Jeffrey R., Muchmore, Douglas B.

“…AIR Inhaled Insulin Versus Subcutaneous Insulin Pharmacokinetics, glucodynamics, and pulmonary function in asthma Michael Wolzt , MD 1 , Amparo de la Peña ,…”
Get full text

Standardized procedure for measurement of nasal potential difference: An outcome measure in multicenter cystic fibrosis clinical trials by Standaert, Thomas A., Boitano, Louis, Emerson, Julia, Milgram, Laura J.H., Konstan, Michael W., Hunter, Janice, Berclaz, Pierre-Yves, Brass, Lois, Zeitlin, Pamela L., Hammond, Keith, Davies, Zoe, Foy, Carla, Noone, Peadar G., Knowles, Michael R.

“…Patients with cystic fibrosis (CF) can be discriminated from healthy subjects by measurement of the nasal potential difference, which has become a useful…”
Get full text

A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate by Genovese, Mark C, Lee, Eric, Satterwhite, Julie, Veenhuizen, Melissa, Disch, Damon, Berclaz, Pierre-Yves, Myers, Stephen, Sides, Gregory, Benichou, Olivier

“…To assess the dose-response relationship, efficacy and safety of tabalumab, a human monoclonal antibody that neutralises membrane-bound and soluble B-cell…”
Get more information

Relationship Between Vertebral Fracture Burden, Height Loss, and Pulmonary Function in Postmenopausal Women With Osteoporosis by Krege, John H, Kendler, David, Krohn, Kelly, Genant, Harry, Alam, Jahangir, Berclaz, Pierre-Yves, Coffey, Barbara, Loghin, Corina

“…Abstract The purpose of this analysis was to assess the association of osteoporosis-related vertebral fracture burden and pulmonary function. This study also…”
Get full text

Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis by Genovese, Mark C, Braun, Daniel K, Erickson, Janelle S, Berclaz, Pierre-Yves, Banerjee, Subhashis, Heffernan, Michael P, Carlier, Hilde

“…To evaluate ixekizumab, an anti-interleukin 17A monoclonal antibody, for safety and effectiveness through 64 weeks in biologic-naive and tumor necrosis…”
Get full text

Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors by Genovese, Mark C, Fleischmann, Roy M, Greenwald, Maria, Satterwhite, Julie, Veenhuizen, Melissa, Xie, Li, Berclaz, Pierre-Yves, Myers, Stephen, Benichou, Olivier

“…To evaluate the efficacy and safety of tabalumab, a monoclonal antibody that neutralises membrane-bound and soluble B-cell activating factor (BAFF), in…”
Get more information

Endocytic Internalization of Adenovirus, Nonspecific Phagocytosis, and Cytoskeletal Organization Are Coordinately Regulated in Alveolar Macrophages by GM-CSF and PU.1 by Berclaz, Pierre-Yves, Zsengeller, Zsuzsanna, Shibata, Yoko, Otake, Kazuhisa, Strasbaugh, Steven, Whitsett, Jeffrey A, Trapnell, Bruce C

“…GM-CSF gene-targeted (GM(-/-)) mice have impaired pulmonary clearance of bacterial and fungal pathogens by alveolar macrophages (AMs). Because AMs also clear…”
Get full text

A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell-activating factor monoclonal antibody, for rheumatoid arthritis by Greenwald, Maria, Szczepanski, Leszek, Kennedy, Alastair, Veenhuizen, Melissa, Komocsar, Wendy J, Polasek, Emery, Guerrettaz, Kelly, Berclaz, Pierre-Yves, Lee, Chin

“…The objective of this study was to evaluate the long-term safety and efficacy of tabalumab, a monoclonal antibody that neutralizes membrane-bound and soluble…”
Get full text

GM-CSF Regulates Alveolar Macrophage Differentiation and Innate Immunity in the Lung through PU.1 by Shibata, Yoko, Berclaz, Pierre-Yves, Chroneos, Zissis C, Yoshida, Mitsuhiro, Whitsett, Jeffrey A, Trapnell, Bruce C

“…GM-CSF gene targeted (GM −/−) mice are susceptible to respiratory infections and develop alveolar proteinosis due to defects in innate immune function and…”
Get full text

Rho GTPase Rac1 is critical for neutrophil migration into the lung by Filippi, Marie-Dominique, Szczur, Kathleen, Harris, Chad E., Berclaz, Pierre-Yves

“…Neutrophils are critical in the inflammatory process by moving rapidly to tissue sites of inflammation. Members of the small Rho GTPase family, Rac1, Rac2,…”
Get full text

GM-CSF, via PU.1, regulates alveolar macrophage FcγR-mediated phagocytosis and the IL-18/IFN-γ–mediated molecular connection between innate and adaptive immunity in the lung by Berclaz, Pierre-Yves, Shibata, Yoko, Whitsett, Jeffrey A., Trapnell, Bruce C.

“…Severely impaired pulmonary microbial clearance was observed in granulocyte-macrophage colony-stimulating factor (GM-CSF)–deficient mice. To determine…”
Get full text

GM-CSF Regulates a PU.1-Dependent Transcriptional Program Determining the Pulmonary Response to LPS by Berclaz, Pierre-Yves, Carey, Brenna, Fillipi, Marie-Dominique, Wernke-Dollries, Kara, Geraci, Nick, Cush, Stephanie, Richardson, Terry, Kitzmiller, Joe, O'Connor, Michael, Hermoyian, Christina, Korfhagen, Thomas, Whitsett, Jeffrey A, Trapnell, Bruce C

“…Alveolar macrophages (AMs) normally respond to lipopolysaccharide (LPS) by activating Toll-like receptor (TLR)-4 signaling, a mechanism critical to lung host…”
Get full text

Efficacy and Safety of Tabalumab, an Anti–B-Cell–Activating Factor Monoclonal Antibody, in a Heterogeneous Rheumatoid Arthritis Population: Results From a Randomized, Placebo-Controlled, Phase 3 Trial (FLEX-O) by Genovese, Mark C, Silverman, Gregg J, Emery, Paul, Gupta, Ramesh C, Gill, Anne, Veenhuizen, Melissa, Xie, Li, Komocsar, Wendy J, Berclaz, Pierre-Yves, Lee, Chin

“…OBJECTIVESThe efficacy and safety of 2 different dosing regimens of tabalumab, a monoclonal antibody that neutralizes membrane-bound and soluble…”
Get full text

Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study by Schiff, Michael, Combe, Bernard, Dörner, Thomas, Kremer, Joel M, Huizinga, Thomas W, Veenhuizen, Melissa, Gill, Anne, Komocsar, Wendy, Berclaz, Pierre-Yves, Ortmann, Robert, Lee, Chin

“…BackgroundTabalumab is a human monoclonal antibody that neutralises B-cell activating factor.ObjectivesTo evaluate tabalumab efficacy and safety in patients…”
Get full text

Internalization of Adenovirus by Alveolar Macrophages Initiates Early Proinflammatory Signaling during Acute Respiratory Tract Infection by Zsengellér, Z, Otake, K, Hossain, S A, Berclaz, P Y, Trapnell, B C

“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Initiation of prandial insulin therapy with AIR inhaled insulin or insulin lispro in patients with type 2 diabetes: A randomized noninferiority trial by Gross, Jorge L, Nakano, Masako, Colon-Vega, Gildred, Ortiz-Carasquillo, Ramon, Ferguson, Jeffrey A, Althouse, Sandra, Tobian, Janet A, Berclaz, Pierre-Yves, Milicevic, Zvonko

“…Insulin initiation in patients with type 2 diabetes is often delayed because of concerns about injections. Our objective was to compare the effects of AIR…”
Get more information

Two-year efficacy and safety of AIR inhaled insulin in patients with type 1 diabetes: An open-label randomized controlled trial by Garg, Satish K, Mathieu, Chantal, Rais, Nadeem, Gao, Haitao, Tobian, Janet A, Gates, Jeffrey R, Ferguson, Jeffrey A, Webb, David M, Berclaz, Pierre-Yves

“…Patients with type 1 diabetes require intensive insulin therapy for optimal glycemic control. AIR((R)) inhaled insulin (system from Eli Lilly and Company,…”
Get more information